[go: up one dir, main page]

MX2017005030A - Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio. - Google Patents

Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio.

Info

Publication number
MX2017005030A
MX2017005030A MX2017005030A MX2017005030A MX2017005030A MX 2017005030 A MX2017005030 A MX 2017005030A MX 2017005030 A MX2017005030 A MX 2017005030A MX 2017005030 A MX2017005030 A MX 2017005030A MX 2017005030 A MX2017005030 A MX 2017005030A
Authority
MX
Mexico
Prior art keywords
compositions
methods
meibomian gland
treatment
disfusion
Prior art date
Application number
MX2017005030A
Other languages
English (en)
Inventor
Friedman Doron
Amselem Shimon
Alster Yair
Rafaeli Omer
Angela Macfarlane K
Reich Cary
Original Assignee
M G Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M G Therapeutics Ltd filed Critical M G Therapeutics Ltd
Publication of MX2017005030A publication Critical patent/MX2017005030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente invención se describen composiciones y métodos para el tratamiento de la disfunción de la glándula de Meibomio. Dichas composiciones y métodos comprenden agentes queratolíticos, tales como ácido salicílico, disulfuro de selenio o similares. La administración tópica de dichas composiciones al borde del párpado y las áreas circundantes proporciona un beneficio terapéutico a los pacientes que sufren de disfunción de glándula de Meibomio.
MX2017005030A 2014-10-19 2015-10-16 Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio. MX2017005030A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462065716P 2014-10-19 2014-10-19
US14/732,622 US9463201B2 (en) 2014-10-19 2015-06-05 Compositions and methods for the treatment of meibomian gland dysfunction
PCT/IB2015/002164 WO2016063130A1 (en) 2014-10-19 2015-10-16 Compositions and methods for the treatment of meibomian gland dysfunction

Publications (1)

Publication Number Publication Date
MX2017005030A true MX2017005030A (es) 2017-12-07

Family

ID=55748155

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005030A MX2017005030A (es) 2014-10-19 2015-10-16 Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio.
MX2021001439A MX2021001439A (es) 2014-10-19 2017-04-18 Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001439A MX2021001439A (es) 2014-10-19 2017-04-18 Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.

Country Status (23)

Country Link
US (9) US9463201B2 (es)
EP (2) EP3206497B1 (es)
JP (4) JP6799532B2 (es)
KR (2) KR102350869B1 (es)
CN (2) CN112972682A (es)
AU (2) AU2015334586B2 (es)
BR (1) BR112017007975A2 (es)
CA (1) CA2964685A1 (es)
CY (1) CY1123821T1 (es)
DK (1) DK3206497T3 (es)
ES (1) ES2848102T3 (es)
HR (1) HRP20210085T1 (es)
HU (1) HUE053485T2 (es)
IL (2) IL251724B (es)
LT (1) LT3206497T (es)
MX (2) MX2017005030A (es)
PL (1) PL3206497T3 (es)
PT (1) PT3206497T (es)
RS (1) RS61295B1 (es)
RU (1) RU2730464C2 (es)
SI (1) SI3206497T1 (es)
SM (1) SMT202100242T1 (es)
WO (1) WO2016063130A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642520B2 (en) 2009-04-01 2017-05-09 Tearscience, Inc. Background reduction apparatuses and methods of ocular surface interferometry (OSI) employing polarization for imaging, processing, and/or displaying an ocular tear film
JP5658228B2 (ja) 2009-04-01 2015-01-21 テイアサイエンス・インコーポレーテツド 眼球涙液膜の画像形成、処理および／または表示を行いおよび／または眼球涙液膜層の厚さを測定する、眼球表面の干渉分光（ｏｓｉ）装置、システムおよび方法
US9888839B2 (en) 2009-04-01 2018-02-13 Tearscience, Inc. Methods and apparatuses for determining contact lens intolerance in contact lens wearer patients based on dry eye tear film characteristic analysis and dry eye symptoms
US9510972B2 (en) 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
US10973680B2 (en) 2012-01-04 2021-04-13 Sight Sciences, Inc. Controller for dry eye treatment systems
US9724230B2 (en) 2012-01-04 2017-08-08 Sight Sciences, Inc. Dry eye treatment apparatus and methods
US9339177B2 (en) 2012-12-21 2016-05-17 Tearscience, Inc. Full-eye illumination ocular surface imaging of an ocular tear film for determining tear film thickness and/or providing ocular topography
WO2014179795A2 (en) 2013-05-03 2014-11-06 Tearscience, Inc. Eyelid illumination systems and methods for imaging meibomian glands for meibomian gland analysis
US9795290B2 (en) 2013-11-15 2017-10-24 Tearscience, Inc. Ocular tear film peak detection and stabilization detection systems and methods for determining tear film layer characteristics
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2017024032A2 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
JP2018533622A (ja) 2015-09-28 2018-11-15 アズーラ オフサルミックス エルティーディー． マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
JP6919970B2 (ja) 2016-04-14 2021-08-18 アズーラ オフサルミックス エルティーディー． マイボーム腺機能不全の処置において使用される二硫化セレン組成物
US20200179305A1 (en) * 2016-04-19 2020-06-11 Azura Ophthalmics Ltd. Compositions for the Treatment of Hyperkeratosis Disorders
KR102541236B1 (ko) * 2017-03-29 2023-06-08 아주라 오프탈믹스 엘티디 마이봄샘 지질 분비 증가를 위한 작용제
EP3618783B1 (en) 2017-05-05 2023-07-05 Craig Litherland Devices for treating eyelids
KR102712798B1 (ko) 2017-11-21 2024-10-04 씨에스 파마슈티컬스 리미티드 안구주위 분비선 또는 안구 표면에서의 이상 염증을 치료하기 위한 조성물 및 사용 방법
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
MX2020007293A (es) 2018-01-12 2021-01-08 Enb Therapeutics Inc Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
US12263115B2 (en) 2018-09-11 2025-04-01 Sight Sciences, Inc. Forceps treatment systems
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
JP7723603B2 (ja) * 2019-04-12 2025-08-14 アズーラ オフサルミックス エルティーディー． コンタクトレンズ不快感を処置するための組成物および方法
KR20210154214A (ko) 2019-04-18 2021-12-20 아주라 오프탈믹스 엘티디 안구 질병의 치료를 위한 화합물 및 방법
EP3955926A4 (en) 2019-04-18 2022-11-30 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP3998933A4 (en) * 2019-08-05 2023-07-19 Sight Sciences, Inc. CONTROL DEVICE WITH IMAGING SYSTEM
CN114980957A (zh) * 2019-11-04 2022-08-30 阿祖拉眼科有限公司 针对眼内或眼周病症的计量剂量
WO2021090058A2 (en) * 2019-11-04 2021-05-14 Azura Ophthalmics Ltd. Metered dose for demodex and disorders related thereto
EP4084803A4 (en) 2020-01-02 2024-02-21 Azura Ophthalmics Ltd Manufacturing of selenium disulfide compositions
WO2021140417A2 (en) * 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
KR20230110516A (ko) * 2020-10-21 2023-07-24 아주라 오프탈믹스 엘티디 눈 장애의 치료를 위한 화합물 및 방법
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
CN117881405A (zh) * 2021-06-24 2024-04-12 阿祖拉眼科有限公司 改善视力的组合物和方法
WO2024100454A2 (en) * 2022-11-11 2024-05-16 Azura Ophthalmics Ltd. Composition and methods for improving signs and symptoms of ocular disorders
WO2025012701A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Administration of keratolytics to ocular and periocular surfaces

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236730A (en) 1962-01-04 1966-02-22 Miles Lab Blepharitis composition comprising antiseptic, quaternary ammonium compound, keratolytic agent and a chelating compound
US5602130A (en) 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5645827A (en) * 1992-09-30 1997-07-08 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
CN1050748C (zh) * 1993-04-22 2000-03-29 孟丽君 表面麻醉涂膜剂的制备方法
JP2891883B2 (ja) 1993-11-05 1999-05-17 学校法人近畿大学 抗白内障医薬組成物
FR2728163A1 (fr) 1994-12-20 1996-06-21 Oreal Composition cosmetique, dermatologique ou pharmaceutique stable contenant du disulfure de selenium et au moins un sel de zinc
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
EP0930072A1 (en) 1998-01-13 1999-07-21 Kartar Dr. Lalvani Vitamin and mineral containing compositions for the treatment of dry eye
JP3407654B2 (ja) 1998-04-14 2003-05-19 ライオン株式会社 眼科用組成物
US6348508B1 (en) 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
FR2832637B1 (fr) 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
FR2833268B1 (fr) 2001-12-12 2005-07-08 Fabre Pierre Dermo Cosmetique Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation
KR100564386B1 (ko) * 2002-05-13 2006-03-27 주식회사 마이코플러스 4-하이드록시-5-메톡시-4-[2-메틸-3-(3-메틸-2-부테닐)-2-옥시란닐]-1-옥사스피로[2,5]옥탄-6-온을 함유한 지루치료용 약제학적 조성물
US8420699B1 (en) 2002-06-19 2013-04-16 Irvine L. Dubow Composition and methods of treatment using deionized and ozonated solution
BR0312817A (pt) 2002-07-23 2005-04-19 Novartis Ag Composição de pomada oftálmica compreendendo uma droga, uma base de pomada e um agente solubilizante/dispersante
AU2003263860A1 (en) 2002-08-19 2004-03-03 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
WO2004028536A1 (en) 2002-09-30 2004-04-08 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20060188471A1 (en) * 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
GB0225795D0 (en) 2002-11-05 2002-12-11 Guillon Michael Wipes
US20070269537A1 (en) * 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
CA2552524A1 (en) 2004-01-10 2005-07-28 Biolipid, Inc. Lipid compositions and methods of use
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20050197614A1 (en) 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US8455016B2 (en) * 2004-03-12 2013-06-04 Melbj Holdings, Llc Treatment for meibomian gland dysfunction or obstruction
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
EP1771214A2 (en) 2004-06-16 2007-04-11 Affinergy Inc. Biofunctional coatings
EP1621191A1 (en) 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
US20090214676A1 (en) 2005-04-30 2009-08-27 Tissuetech, Inc. Method for treating ocular demodex
JPWO2006137426A1 (ja) 2005-06-22 2009-01-22 興和株式会社 角結膜疾患の予防又は治療剤
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
EP1968379A2 (en) 2005-12-12 2008-09-17 Riolan Technologies, Inc. Compositions, methods and kits for removing debris from an ocular area
RU2314102C1 (ru) * 2006-04-07 2008-01-10 Федеральное государственное учреждение "МОСКОВСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ имени ГЕЛЬМГОЛЬЦА ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Способ комплексного лечения дисфункции мейбомиевых желез
WO2007133703A2 (en) 2006-05-10 2007-11-22 Dxterity Diagnostics Detection of nucleic acid targets using chemically reactive oligonucleotide probes
US8568790B2 (en) 2006-05-31 2013-10-29 Medihoney Pty Ltd. Medicinal compositions containing honey
US20090123527A1 (en) * 2006-07-24 2009-05-14 Akorn, Inc. Method of inducing topical anesthesia and transdermal patch
US20080021068A1 (en) * 2006-07-24 2008-01-24 Akorn, Inc. Aqueous gel formulation and method for inducing topical anesthesia
WO2008027069A1 (en) * 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
US8249695B2 (en) 2006-09-29 2012-08-21 Tearscience, Inc. Meibomian gland imaging
US8090426B2 (en) 2006-10-27 2012-01-03 Felder Robin A Microelectronic biosensor plug
CA2668414C (en) * 2006-11-03 2015-02-10 Qlt Inc. Methods of treating dermatological disorders or conditions
JP4987078B2 (ja) 2006-11-30 2012-07-25 株式会社メニコン 眼科用組成物
BRPI0808410A2 (pt) 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
EP2136800A4 (en) 2007-03-19 2011-10-05 Wisconsin Alumni Res Found MODULATION OF BACTERIAL QUORUM DETECTION WITH SYNTHETIC LIGANDS
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
WO2009120881A1 (en) 2008-03-26 2009-10-01 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin desease using tetracycline family antibiotics
CN102105137B (zh) 2008-04-30 2015-01-07 Qlt股份有限公司 复合泪管植入物及相关方法
CA2730108A1 (en) 2008-07-10 2010-01-14 Allergan, Inc. Cyclosporin derivatives for treating ocular and dermal diseases and conditions
US20120028929A1 (en) 2008-09-19 2012-02-02 Alacrity Bioscience, Inc. Tetracycline stabilizing formulations
US9888839B2 (en) 2009-04-01 2018-02-13 Tearscience, Inc. Methods and apparatuses for determining contact lens intolerance in contact lens wearer patients based on dry eye tear film characteristic analysis and dry eye symptoms
AU2010242866B2 (en) 2009-05-01 2014-09-25 Medtech Products Inc. Cleanser compositions and methods for using the same
WO2011006079A2 (en) 2009-07-10 2011-01-13 Lyotropoic Therapeutics, Inc. Ophthalmic formulations of reversed liquid crystalline phase materials and methods of using
CN101612161A (zh) * 2009-08-07 2009-12-30 魏谠全 一种眼药组合物及其制剂
CN102038953B (zh) * 2009-10-14 2012-07-18 上海昊海生物科技股份有限公司 一种眼科手术前局部麻醉用组合物及其制备方法和用途
US20110104083A1 (en) 2009-10-30 2011-05-05 Intratus, Inc. Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
WO2011068786A2 (en) 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
JP2013516501A (ja) 2010-01-11 2013-05-13 ジーティーエックス・インコーポレイテッド マイボーム腺機能障害を治療する方法
JP5931847B2 (ja) * 2010-03-31 2016-06-08 オキュジェクト， エルエルシー 眼内薬剤送達のためのデバイスおよび方法
DE102010026696A1 (de) * 2010-07-06 2012-01-12 Nadja Knop Fettstift zur medizinischen Applikation von Wirkstoffen auf den Rand des Augenlides
US8304840B2 (en) 2010-07-29 2012-11-06 Taiwan Semiconductor Manufacturing Company, Ltd. Spacer structures of a semiconductor device
US20120093876A1 (en) 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
JP2013543862A (ja) 2010-11-08 2013-12-09 ヒールオア・リミテッド 眼科用緩衝組成物およびその使用方法
US20140031341A1 (en) * 2010-12-22 2014-01-30 Universitat Munster Modulators and methods for the treatment of rosacea
WO2012092378A1 (en) 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating blepharitis
WO2012092320A2 (en) 2010-12-29 2012-07-05 Nichamin Louis D Eye treatment
WO2012092375A1 (en) 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating dry eye
RU2599036C2 (ru) 2011-01-26 2016-10-10 Аллерган, Инк. Андрогенная композиция для лечения офтальмологического заболевания
MX360666B (es) * 2011-05-12 2018-11-13 Foresight Biotherapeutics Inc Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
BR112013029592A2 (pt) 2011-05-20 2019-09-24 Univ Keio "metaloproteína e processo para produção desta, e a gente profilático ou terapêutico para doenças corneanas e conjuntivais compreendendo a dita metaloproteína"
JP2014518275A (ja) 2011-06-29 2014-07-28 インサイト・ビジョン・インコーポレイテッド 再発性マイボーム腺障害の処置方法およびそれによる再発頻度の減少方法
ITFI20120044A1 (it) 2012-03-01 2013-09-02 Biodue Spa Formulazione ad uso oftalmico comprendente olio di jojoba.
KR102113998B1 (ko) 2012-04-16 2020-05-25 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 피부 및／또는 점막의 치료 및／또는 관리용 화합물 및 미용적 또는 약학적 조성물에서의 이의 용도
EP2664330A1 (de) 2012-05-15 2013-11-20 F. Holzer GmbH Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan
EP2922536A4 (en) 2012-11-20 2016-06-08 Revive Therapeutics Inc USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
US9211397B2 (en) 2012-12-19 2015-12-15 Senju Usa, Inc. Patch for treatment of eyelid disease containing clobetasol
US20140206708A1 (en) 2013-01-24 2014-07-24 Rigel Pharmaceuticals, Inc. Composition for ophthalmic administration
LT2950783T (lt) * 2013-02-01 2019-10-25 Allergan Inc Dirbtinės ašaros, kurių sudėtyje yra natrio hialuronato ir karboksimetilceliuliozės
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
PL3033336T3 (pl) 2013-08-14 2018-11-30 Kalvista Pharmaceuticals Limited Inhibitory kalikreiny w plaźmie
AU2015257874B2 (en) 2014-05-07 2019-11-28 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
AU2015269353B2 (en) 2014-06-04 2020-03-26 Tersus Pharmaceuticals, LLC Methods of treating chronic dry eye disease using C16:1n7 palmitoleate and derivatives thereof
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2016066195A1 (en) 2014-10-29 2016-05-06 Laboratoire Medidom Sa Heat-sterilized formulation comprising chitosan and process of preparation thereof
US20180043024A1 (en) 2015-03-03 2018-02-15 Nof Corporation Eyedrops
JP2018533622A (ja) 2015-09-28 2018-11-15 アズーラ オフサルミックス エルティーディー． マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
CN105456287B (zh) 2015-12-03 2017-06-30 大有药业扬州有限公司 二硫化硒超微粉体及其制备方法
JP6919970B2 (ja) 2016-04-14 2021-08-18 アズーラ オフサルミックス エルティーディー． マイボーム腺機能不全の処置において使用される二硫化セレン組成物
US20200179305A1 (en) 2016-04-19 2020-06-11 Azura Ophthalmics Ltd. Compositions for the Treatment of Hyperkeratosis Disorders
JP7723603B2 (ja) 2019-04-12 2025-08-14 アズーラ オフサルミックス エルティーディー． コンタクトレンズ不快感を処置するための組成物および方法

Also Published As

Publication number Publication date
EP3206497B1 (en) 2020-12-02
PT3206497T (pt) 2021-02-05
HRP20210085T1 (hr) 2021-03-05
PL3206497T3 (pl) 2021-05-04
LT3206497T (lt) 2021-02-25
JP2017531668A (ja) 2017-10-26
JP2024150506A (ja) 2024-10-23
EP3831396A1 (en) 2021-06-09
US20160106775A1 (en) 2016-04-21
US12447162B2 (en) 2025-10-21
US20240350517A1 (en) 2024-10-24
CN107105669B (zh) 2021-02-09
SMT202100242T1 (it) 2021-05-07
US12427158B2 (en) 2025-09-30
CN112972682A (zh) 2021-06-18
BR112017007975A2 (pt) 2018-01-23
CN107105669A (zh) 2017-08-29
US20190388440A1 (en) 2019-12-26
HUE053485T2 (hu) 2021-06-28
KR20210061467A (ko) 2021-05-27
US11013749B2 (en) 2021-05-25
US10034887B2 (en) 2018-07-31
AU2015334586B2 (en) 2019-12-19
JP2023062705A (ja) 2023-05-08
CA2964685A1 (en) 2016-04-28
US10772899B2 (en) 2020-09-15
US12048707B2 (en) 2024-07-30
RU2730464C2 (ru) 2020-08-24
US20200330488A1 (en) 2020-10-22
WO2016063130A1 (en) 2016-04-28
KR20170095825A (ko) 2017-08-23
US20230218642A1 (en) 2023-07-13
IL280209A (en) 2021-03-01
KR102255726B1 (ko) 2021-05-27
JP6799532B2 (ja) 2020-12-16
AU2020201548A1 (en) 2020-03-19
DK3206497T3 (da) 2020-12-21
RS61295B1 (sr) 2021-02-26
US20190125766A1 (en) 2019-05-02
US10588915B2 (en) 2020-03-17
AU2015334586A1 (en) 2017-05-25
EP3206497A1 (en) 2017-08-23
KR102350869B1 (ko) 2022-01-14
US11633410B2 (en) 2023-04-25
MX2021001439A (es) 2021-04-12
ES2848102T3 (es) 2021-08-05
JP2020169181A (ja) 2020-10-15
EP3206497A4 (en) 2018-06-06
US20210236518A1 (en) 2021-08-05
IL251724B (en) 2021-01-31
SI3206497T1 (sl) 2021-03-31
CY1123821T1 (el) 2022-05-27
RU2017115563A3 (es) 2019-02-14
US20170035785A1 (en) 2017-02-09
US9463201B2 (en) 2016-10-11
RU2017115563A (ru) 2018-11-20
US20240350516A1 (en) 2024-10-24
IL251724A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
MX2017005030A (es) Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio.
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
EA201691582A1 (ru) Новые фармацевтические препараты
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
MX2018012390A (es) Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfuncion de las glandulas de meibomio.
PE20160123A1 (es) Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio
EA201691808A8 (ru) Кортикостероидные композиции для местного применения
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CO2017003321A2 (es) Inhibidores de gingipaina de lisina
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales